biology and background for ctdna; advantages and drawbacks … · 2016. 12. 7. · amg 208 bard 101...
TRANSCRIPT
![Page 1: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/1.jpg)
Biology and Background for ctDNA; Advantages and Drawbacks of Assays Currently in Use; Knowledge Gaps
Luis Diaz, M.D.Workshop on Circulating Tumor DNA assays in Clinical Cancer Research
Cancer Diagnosis Program, NCISeptember 29, 2016
![Page 2: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/2.jpg)
I have the following financial relationships to disclose:
Founder and shareholder in Pagerbox, Papgene and Personal Genome Diagnostics, Inc.
Consultant for Merck, Illumina, PGDx and Cell Design Labs
PapGene and Personal Genome Diagnostics (PGDx) s, as well as other companies, have licensed technologies from Johns Hopkins University, on which LD is an inventor. These licenses and relationships are associated with equity or royalty payments. The terms of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies.
Disclosure Information
![Page 3: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/3.jpg)
Clinical Application of Cancer Genetics
Mutations as Biomarkers
![Page 4: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/4.jpg)
Clinical Application of Cancer Genetics
Somatic Cancer
Genome Data
Prognostic Markers
Immune Antigens
Predictive Markers
Dynamic Biomarkers
![Page 5: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/5.jpg)
Mutations are highly specific
Cancer Cell
Normal Cells
Pre-Cancer Cell
Mutations No Mutations
![Page 6: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/6.jpg)
Access to Somatic Mutations
Tumor Tissue• FFPE• Frozen tissue
Blood & other bodily fluids• Cell-free DNA• Circulating tumor cells (CTCs)
![Page 7: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/7.jpg)
Mutant RAS in stool from patients with CRC
Sidransky et. als., Science. VOL 256 3 APRL 1992
![Page 8: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/8.jpg)
Clinical Application of Cancer Genetics
Liquid Biopsies
![Page 9: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/9.jpg)
• DNA fragments of 120-200bp with half life of ~2 hours
• Real-time, non-invasive, multi-lesions, potentially cheaper (considering cost of biopsies)
• Often very low amount of ctDNA in the sea of wild type DNA - ”Needle in a farm”
• Specific to tumor
![Page 10: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/10.jpg)
Liquid Biopsy
PlasmaWater 91%Proteins 7%Metabolites (trace)Cell-free DNA (trace)
Cellular ComponentsWhite Blood Cells 2-3%Platelets 2-3%Red Blood Cells 90%Circulating tumor cells (trace)
![Page 11: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/11.jpg)
Source circulating cell-free DNA
Bone Marrow GI Tract Skin
Pool of Cell-free DNA
Fetal DNA
![Page 12: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/12.jpg)
Source circulating cell-free DNA
Bone Marrow GI Tract Skin
Pool of Cell-free DNA
Transplanted Tissue DNA
![Page 13: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/13.jpg)
Source circulating cell-free DNA
Bone Marrow GI Tract Skin
Pool of Cell-free DNA
Tumor DNA
![Page 14: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/14.jpg)
Schematic illustration of the principle of plasma DNA tissue mapping by genome-wide methylation sequencing and its applications.
Kun Sun et al. PNAS 2015;112:E5503-E5512
©2015 by National Academy of Sciences
![Page 15: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/15.jpg)
Percentage contributions of different tissues to plasma DNA for 15 pregnant women.
Kun Sun et al. PNAS 2015;112:E5503-E5512
©2015 by National Academy of Sciences
![Page 16: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/16.jpg)
Cell-free DNA – origin
180bp
360bp
540bp
ApoptosisNecrosis
Jahr, S. Cancer Res, 2001
![Page 17: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/17.jpg)
Normal
Tumor
Circulating cell-free DNA in a Cancer Patient
![Page 18: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/18.jpg)
Wild-type
Mutant
Circulating cell-free DNA in a Cancer Patient
![Page 19: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/19.jpg)
Technology to assess circulating tumor DNADigital PCR• Best for individual point mutations but can be used for crude copy number analysis• Mutation needs to known ahead of time (ie BRAF v600e)• Sensitivity is dependent on specific mutation and assay optimization• Multiplexing assay is possible• Fast and highly reproducible – results in hours• Minimal bioinformatics needs• Inexpensive
Next-generation Sequencing• Evaluates genomic regions of interest using PCR or capture-based methods• Has been used for point mutations, rearrangements, genomic amplification, aneuploidy, whole exome
and whole genome sequencing• High false discovery rate that requires pre-sequencing barcoding and post-sequencing bioinformatics
for error suppression • Expensive• Turnaround time 1-2 days at best
![Page 20: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/20.jpg)
Digital PCR
Diehl et al Nature Medicine, 2008
• BEAMing – emusion-digital PCR
• Sensitivity – 0.01% (depends on mutation)
• Mutation to be tested needs to be known ahead of time
![Page 21: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/21.jpg)
BEAMing
DevinDressman
Diehl et al Nature Medicine, 2008Dressman et al. PNAS
![Page 22: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/22.jpg)
Before Surgery Day 0
After Surgery Day 1
After Surgery Day 42
CT scan negative
After Surgery Day 244
CT scan positive
13.4 % 0.015 % 0.11 % 0.66 %
Percent Mutant APC
Wild-type fragments
Mutant fragmentsDiehl et al Nature Medicine, 2008
![Page 23: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/23.jpg)
Safe-SeqS – NGS approach to detect ctDNA
Amplification
Ken Kinzler
B. Vogelstein
N. Papadopoulos
Isaac Kinde
Kinde et al. PNAS
![Page 24: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/24.jpg)
Safe-SeqS – NGS approach to detect ctDNA
Amplification
• NGS-based approach
• Scans multiple ROIs
• Sensitivity – 0.01% (depends on mutation)
• Mutation does not need to be known ahead of time
![Page 25: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/25.jpg)
Applications of ctDNA
• Genotyping cancer & identify actionable genetic alterations• For patients lack tissue for molecular analysis • For patients whose tumors have evolved over time and treatment (too
risky to perform or after relapse when biopsies are not routine)• Discordance between mutations in primary/metastases lesions• Acquired resistance (e.g., patients who develop resistance to EGFR blockade)
• Monitoring of tumor burden / response to treatment (vs. CEA or imaging)• Detection of Occult Disease
• Minimal Residual Disease• Early Detection/Screening
![Page 26: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/26.jpg)
Potential of Liquid Biopsies in Precision Medicine
Monitoring tumor dynamics
![Page 27: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/27.jpg)
Molecular Analysis
FrankDiehl
KerstinSchmidt
FrankDiehl
KerstinSchmidt
![Page 28: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/28.jpg)
-100
-50
0
50
100
150
200
0.00 50.00 100.00 150.00 200.00 250.00
DAYS
ctDNA levels
Initiation of GTXC
ctDNA Spike
Circulating tumor DNA is a rapidly dynamic biomarker
Partial Response
![Page 29: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/29.jpg)
-100
-80
-60
-40
-20
0
20
40
60
0.00 100.00 200.00 300.00 400.00 500.00
CTDNA VS CA19-9 ctDNA Spike
CA19-9Break
GTXCBreak
![Page 30: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/30.jpg)
Circulating Tumor DNA as an Early Indicator of Response to T-Cell Transfer Immunotherapy 2 in Metastatic Melanoma
Patients with CR
![Page 31: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/31.jpg)
Clinical Application of Cancer Genetics
Tracking Resistance
![Page 32: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/32.jpg)
Diaz et al Nature, 2012.
Tracking Resistance
• Understand the molecular resistance to EGFR blockade in colorectal cancer
• Patients are KRAS WT prior to initiate therapy
• Monitoring the emergence of resistant mutations in KRAS WT patients treated with EGFR blockade
![Page 33: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/33.jpg)
Bettegowda et al, Sci Tran Med 2014
Tracking Resistance
Sample ID KR
AS
12
KR
AS
13
KR
AS
61
NR
AS
12
NR
AS
61
BR
AF
600
EG
FR 7
94
EG
FR 7
14
KR
AS
12
KR
AS
13
KR
AS
61
NR
AS
12
NR
AS
61
BR
AF
600
EG
FR 7
14
EG
FR 7
94
AMG 011AMG 022AMG 028AMG 034AMG 040AMG 046AMG 105AMG 109AMG 114AMG 121AMG 126AMG 132AMG 140AMG 148AMG 155AMG 161AMG 167AMG 180AMG 188AMG 195AMG 208
BARD 101 PLSBARD 102 PLSBARD 103 PLSCRC 188 PLSCRC 189 PLSCRC 190 PLSCRC 191 PLS
Single mutationMultiple mutations
Pre-Treatment Post-Treatment
• Interrogated all exons of KRAS, NRAS, BRAF, PIK3CA and EGFR
• 96% of cases had at least 1 mutation KRAS or NRAS
![Page 34: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/34.jpg)
Janku, F. et al. (2010) Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2010.64
![Page 35: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/35.jpg)
Janku, F. et al. (2010) Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2010.64
X
X
X95%
X <5%
<5%
<5%
![Page 36: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/36.jpg)
WGS of plasma DNA in EGFR resistant CRC patient
A total of 630 Gb of sequence data were obtained, corresponding to 145x sequence coverage of cell-free plasma genomic DNA.
Identified in plasma sample following clinical resistance:• Q61H mutation in KRAS • focal high-level (>9 fold) amplification of MET• focal high-level (>3 fold) amplification of CDK8
These were not detected in pre-treatment tumor samples
![Page 37: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/37.jpg)
Tracking ResistanceEGFR BLOCKADE
KRAS WTNRAS WTEGFR WTMET WT
KRAS Mutant
EGFR Mutant
NRAS Mutant
MET Amplified
![Page 38: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/38.jpg)
Potential of Liquid Biopsies in Precision Medicine
Molecular Remission
![Page 39: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/39.jpg)
ctDNA monitoring in patients with diffuse large B-cell lymphoma
• 108 patients
• VDJ gene segments of the rearranged immunoglobulin receptor genes
• ctDNA measured after 2 cycles of therapy
*National Cancer Institute and Adaptive Biotechnologies
Roschewski M et al. Lancet Oncol. 2015.
![Page 40: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/40.jpg)
Clearance of circulating EGFR mutations in metastatic lung cancer
• 122 patients with EGFR mutant NSCLC
• Treated with erlotinib-based regimen
• Determined using allele-specific PCR after 3 cycles of therapy
*Hong Kong Cancer Institute, Roche, Genentech
Mok T et al. Clin Cancer Res. 2015.
![Page 41: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/41.jpg)
Monitoring response to checkpoint inhibitors using ctDNA
41
ctDNA levels increased initially as lymphadenopathy progressed by examination, but then became undetectable 3 weeks prior to clinical improvement.
Lipson et al. J. of Immunotherapy 2014.
![Page 42: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/42.jpg)
Clinical Application of Cancer Genetics
Minimal Residual Disease
![Page 43: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/43.jpg)
What is Minimal Residual Disease (MRD)?
Cured
NotCured
Minimal Residual Disease
None
Present
Definitive Therapy(potentially curative)
ChemotherapySurgery
RadiationImmunotherapy
![Page 44: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/44.jpg)
What is Minimal Residual Disease (MRD)?
Cured
NotCured
Minimal Residual Disease
None
Present
Definitive Therapy(potentially curative)
ChemotherapySurgery
Radiation
![Page 45: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/45.jpg)
Imaging (FDG-PET or CT Scan)• Poor sensitivity for microscopic disease• Variable specificity
Protein Biomarkers(e.g. CA19-9, CEA, CA-125)• Long half-life• Often Non-specific
CTCs• Poor sensitivity for microscopic disease• Does not localize disease
Circulating Nucleic Acids• Does not localize disease• Highly specific
Systemic Approaches to Detect MRD
![Page 46: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/46.jpg)
Molecular Analysis
FrankDiehl
KerstinSchmidt
![Page 47: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/47.jpg)
Before Surgery Day 0
After Surgery Day 1
After Surgery Day 42
CT scan negative
After Surgery Day 244
CT scan positive
13.4 % 0.015 % 0.11 % 0.66 %
Percent Mutant APC
Wild-type fragments
Mutant fragmentsDiehl et al Nature Medicine, 2008
![Page 48: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/48.jpg)
CEA measured 6-8 weeks following curative resection of mCRC
Diehl et al Nature Medicine, 2008
![Page 49: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/49.jpg)
ctDNA measured 6-8 weeks following curative resection of mCRC
Diehl et al Nature Medicine, 2008
![Page 50: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/50.jpg)
250* patients with Stage II colon cancer
4-10 weeks post-op blood samples
Tumor Tissue
- Use of adjuvant chemo at clinician’s
discretion - 3-monthly clinical
review - 6-monthly
restaging CT
Massively parallel sequencing of TP53, APC, KRAS, BRAF,
PIK3CA, FBXW7 and SMAD4 mutations
Mutations identified in
tumors
- ctDNAquantification with
Safe-SeqS- CEA analysis
Recurrence and survival data
3-monthly follow-up blood draw
(N = 175)
J. Tie and Peter Gibbs
![Page 51: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/51.jpg)
51
ctDNA measured 6-8 weeks following curative resection of stage II CRC
J. Tie and Peter Gibbs, ASCO 2015
![Page 52: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/52.jpg)
MRD detection with ctDNA in breast cancer.
Isaac Garcia-Murillas et al., Sci Transl Med 2015;7:302ra133
Published by AAAS
![Page 53: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/53.jpg)
Philosophy of Early Detection
![Page 54: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/54.jpg)
Philosophy of Early Detection
![Page 55: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/55.jpg)
Clinical Application of Cancer Genetics
Early Detection – Blood
![Page 56: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/56.jpg)
Early Detection using ctDNA Analyses
Bettegowda et al, Sci Tran Med Feb 2014
14 Tumor types (n = 684)
![Page 57: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/57.jpg)
Early Detection using ctDNA Analyses
Bettegowda et al, Sci Tran Med Feb 2014
![Page 58: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/58.jpg)
JAMA. 2015;314(2):162-169.
Detection of Occult Malignancy from analyses of cell free fetal DNA
125,426 NIPT tests3757 (3%) positive for 1 or more aneuploidies 10 cases of maternal cancer were identified
36 year old female at 20 weeks gestationMonosomy in chromosomes 21, 18 and 13 persisted post-deliveryDiagnosed with stage IIA Hogdkin disease
![Page 59: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/59.jpg)
Detection of Occult Malignancy from analyses
of cell free fetal DNA
Nilesh Dharajiya et al. AMP Abstract 2015
400,000 NIPT Tests38 confirmed aneuploidies with neoplasm17 Mutant, 15 benign, 6 Unclassified
![Page 60: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/60.jpg)
-540
-370
-200
-30-30-20-10
010203030
200370540
Chr. Arm Gain
Chr. Arm Loss
Diploid
N1 N2
N3
N4
CRC11
CRC12
CRC13
CRC14
N5
N6
N7
N8
N9
N10
BR3
BR2
BR1
CRC17
CRC16
CRC15
z-sc
ore
Leary, Sausen, and Kinde et al. Sci Transl Med. 2012 Nov 28;4(162):162ra154.
Aneuploidy in normal in cancer patients ctDNA
![Page 61: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/61.jpg)
Clinical Application of Cancer Genetics
Early Detection – Saliva
![Page 62: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/62.jpg)
See
Yuxuan Wang et al., Sci Transl Med 2015;7:293ra104
Sensitivity
![Page 63: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/63.jpg)
Clinical Application of Cancer Genetics
Early Detection – Pap Smears
![Page 64: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/64.jpg)
![Page 65: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/65.jpg)
Early Detection - GenePap
![Page 66: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/66.jpg)
Somatic Mutation as Biomarkers
Stool DNA Colon Tumor cells >50%
Urine DNA Bladder Mixture 80%
Blood All Cancers Cell-free DNA 60%
Pap Smears
Endometrial Mixture 95%
Ovarian Mixture 40%
Saliva Head & Neck
Cell-free DNA >80%
Fluid Tumor DNA Source Sensitivity*
*Stage I and II Disease
![Page 67: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/67.jpg)
Clinical Application of Cancer Genetics
Challenges
![Page 68: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/68.jpg)
Not all clonal events are cancer
Whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons somatic mutations characteristic of hematologic malignancies were observed in 10% of persons older than 65 years of age
Genovese et al., N Engl J Med 2014; 371:2477-2487
![Page 69: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/69.jpg)
Genovese G et al. N Engl J Med 2014;371:2477-2487.
Candidate Driver Somatic Mutations.
![Page 70: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/70.jpg)
LocalizationCASE: A 55 year old male was found to have a persistent KRAS mutation (G12D) in ctDNA at >0.8%
CT Scan, PET Scan, Colonoscopy and PSA are normal.
What is this? Lung, Colon Pancreas?
![Page 71: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/71.jpg)
Matthew W. Snyder, Martin Kircher, Andrew J. Hill, Riza M. Daza, Jay Shendure
Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin
Cell, Volume 164, Issues 1–2, 2016, 57–68
![Page 72: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/72.jpg)
Heterogeneity• ~80% late stage
tumors shed ctDNA
• Anatomic barriers to tumor DNA release into circulation
• Heterogeneity in shedding
![Page 73: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/73.jpg)
Future for ctDNA
Incremental improvements in technology• Increase in comprehensive panels• Limited by biology more that technology • Need a biologic based discovery to drive dramatic improvement
![Page 74: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/74.jpg)
Future for ctDNA
Incremental improvements in technology• Increase in comprehensive panels• Limited by biology more that technology • Need a biologic based discovery to drive dramatic improvement
Clinical Application• Tumor genotyping in plasma will be integrate into routine practice
– based on concordance studies• High impact applications that drive improvements in OS will
require prospective clinical trials and partnership with FDA.
![Page 75: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/75.jpg)
Summary
Point Mutations
Regions of Interest
Structural Changes/Exome
Whole Genome
Targeted
Unbiased
$$$
Cost of Sequencing
![Page 76: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/76.jpg)
Summary
Somatic mutations can be effective biomarkers largely because of specificity
Digital Genomics has improved sensitivity and throughput sufficient for real clinical application
Applications for detecting occult disease for minimal residual disease detection and screening for cancer
Broad commercialization will require overcoming cost, regulatory, payor and definitive clinical studies demonstrating clinical benefit.
![Page 77: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/77.jpg)
Acknowledgments
![Page 78: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/78.jpg)
AcknowledgmentsAcknowledgments
![Page 79: Biology and Background for ctDNA; Advantages and Drawbacks … · 2016. 12. 7. · AMG 208 BARD 101 PLS BARD 102 PLS BARD 103 PLS CRC 188 PLS CRC 189 PLS CRC 190 PLS CRC 191 PLS](https://reader033.vdocuments.mx/reader033/viewer/2022051804/5ff08f7bce3aa94ee24d0ccf/html5/thumbnails/79.jpg)
Thank you
V. VelculescuKen KinzlerB. Vogelstein Shibin ZhouN. Papadopoulos